President Trump’s Cannabis Rescheduling Opens the Door to a Trillion-Dollar Industry—With the United States Back in the Lead

For decades, U.S. cannabis policy was driven more by stigma than science. Presidents promised reform. Federal agencies studied the issue. Patients and researchers waited. Meanwhile, an entire global industry—spanning pharmaceuticals, biotechnology, wellness, agriculture, and advanced manufacturing—remained artificially constrained by outdated federal law.

That changed when Donald Trump directed the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.

This was not merely a regulatory adjustment. It was a market-defining decision—one that removes structural barriers to capital formation, institutional research, and global scale.

In practical terms, it opens the door to what is increasingly understood as a future trillion-dollar global industry, with the United States once again positioned to lead.

Why Cannabis Rescheduling Is an Economic Inflection Point

Rescheduling cannabis does not legalize it federally. Instead, it does something far more consequential for markets: it allows cannabis and cannabinoids to move through the same research-to-commercialization pipeline that governs pharmaceuticals, biotech, and regulated consumer products.

Schedule I status previously blocked:

• Federally funded medical research

• Institutional and pension-fund investment

• Pharmaceutical and biotech participation

• FDA-adjacent development pathways

• Scalable manufacturing and global trade

Schedule III removes those barriers.

That shift fundamentally changes the industry’s risk profile, valuation framework, and capital accessibility—the prerequisites for large, durable markets.

Hard Market-Size Estimates by Sector

When investors talk about a “trillion-dollar cannabis industry,” they are not referring to today’s dispensary sales. They are referring to the full vertical integration of cannabinoids across multiple global sectors.

Below is where the scale comes from.

Pharmaceuticals & Therapeutics

• Global pharmaceutical market: $1.5+ trillion annually

• Cannabinoid-based drugs (pain, oncology, neurology, inflammation, mental health) could conservatively capture 5–10% over time

• $150–300 billion addressable opportunity

Biotechnology & Precision Medicine

• Global biotech market: $1.3+ trillion by early 2030s

• Cannabinoids as signaling molecules, delivery mechanisms, and adjunct therapies

• $200–300 billion long-term potential

Health, Wellness & Consumer Therapeutics

• Global wellness market: $4.5+ trillion

• Includes CBD, minor cannabinoids, functional foods, nutraceuticals, sleep, aging, and mental health

• Even modest penetration yields $300–500 billion

Agriculture, Hemp & Industrial Applications

• Global ag-biotech, bio-materials, textiles, and sustainable inputs

• Hemp-derived inputs in plastics, building materials, fuels, and carbon-negative products

• $100–200 billion opportunity

Combined Long-Term Addressable Market

➡️ $800 billion to well over $1 trillion globally as research, regulation, and capital converge.

What I’ve Seen Firsthand

I’ve spent the last decade working directly in public policy, cannabis and hemp licensing, regulatory compliance, and research initiatives—after more than 25 years in political strategy and government relations.

I’ve collaborated with U.S. universities and international partners on cannabis and hemp research projects. But those efforts were consistently limited in scope and funding—not because the science lacked promise, but because Schedule I status made serious research, IP development, and commercialization nearly impossible.

Capital stayed sidelined. Institutions stayed away. Innovation moved offshore.

That constraint is now lifting.

Global Markets Were Moving—Now the U.S. Can Set the Standard

While federal policy stalled, other nations advanced medical and adult-use cannabis frameworks. Germany, the United Kingdom, Japan, Australia, Israel, and Thailand moved forward—much like U.S. states such as California and Colorado did domestically.

Yet even globally, large-scale, FDA-caliber cannabinoid research remained limited. Without U.S. regulatory leadership and capital markets, the industry lacked a true center of gravity.

Rescheduling restores that center.

When the United States leads in regulation, research standards, and capital formation, global markets align. That alignment is how trillion-dollar industries are built.

Why Research Unlocks Scale (and Valuation)

Moving cannabis out of Schedule I is not symbolic—it is foundational.

It enables:

• Federally funded, multi-site clinical trials

• Pharmaceutical and biotech R&D participation

• IP-protected cannabinoid formulations

• Integration into mainstream healthcare systems

This is how cannabis evolves from a fragmented commodity market into a high-value medical and scientific platform—the difference between short-term speculation and long-term institutional investment.

Capital Markets, Tax Policy, and Institutional Entry

Schedule III status also removes the IRS Section 280E penalty, allowing cannabis companies to deduct ordinary operating expenses.

For investors, this means:

• Improved margins and cash flow

• More predictable financials

• Increased M&A viability

• Eligibility for broader capital participation

This is not deregulation. It is market maturation.

Sidebar: Why This Is a Trillion-Dollar Industry

Cannabis reaches trillion-dollar scale because it is not one industry—it is a platform.

• It touches pharmaceuticals, biotech, wellness, agriculture, and materials science• It shifts from commodity products to IP-driven therapies• It moves through regulated global supply chains• It attracts institutional capital once risk barriers fall• It scales internationally once standards align

Every trillion-dollar industry—pharma, energy, technology—followed this same trajectory.

Cannabis is now positioned to do the same.

The Strategic Moment

For too long, the United States ceded leadership in cannabinoid science and commercialization to other nations. President Trump’s decision marks a decisive pivot—reconnecting science, policy, and capital.

If sustained, this shift will modernize domestic cannabis policy and accelerate long-delayed medical discoveries—while opening the door to a trillion-dollar global industry with the United States firmly back in the lead. That outcome is made possible by President Trump’s leadership in advancing science, patient care, and evidence-based reform.

About the Author

Brandon Gesicki is a Government Relations, Business, and Licensing Consultant and a partner in cannabis businesses. He has worked in political strategy, government affairs, and regulatory advocacy for more than 25 years. He has successfully advocated for cannabis and hemp research and collaborated with universities and international partners on cannabis and hemp research initiatives. He advises businesses on licensing, regulatory compliance, and government relations across multiple jurisdictions.